William Blair restated their outperform rating on shares of Dynavax Technologies Corp. (NASDAQ:DVAX) in a research report sent to investors on Saturday. William Blair currently has a $17.00 target price on the biopharmaceutical company’s stock, down from their prior target price of $45.00.

A number of other brokerages have also recently issued reports on DVAX. Zacks Investment Research cut Dynavax Technologies Corp. from a hold rating to a sell rating in a research note on Thursday, November 10th. S&P Equity Research upped their price objective on Dynavax Technologies Corp. from $11.28 to $16.01 in a research note on Friday, September 2nd. RBC Capital Markets reissued a sector perform rating and set a $16.00 target price on shares of Dynavax Technologies Corp. in a report on Wednesday, September 7th. Finally, Cowen and Company reissued an outperform rating and set a $45.00 target price on shares of Dynavax Technologies Corp. in a report on Tuesday, September 6th. One research analyst has rated the stock with a sell rating, three have given a hold rating and two have issued a buy rating to the company. Dynavax Technologies Corp. presently has a consensus rating of Hold and an average target price of $20.14.

Shares of Dynavax Technologies Corp. (NASDAQ:DVAX) traded up 4.44% on Friday, hitting $4.70. The company’s stock had a trading volume of 2,090,983 shares. Dynavax Technologies Corp. has a 52 week low of $3.20 and a 52 week high of $29.86. The stock’s 50-day moving average price is $9.63 and its 200-day moving average price is $13.43. The firm’s market cap is $181.08 million.

Dynavax Technologies Corp. (NASDAQ:DVAX) last announced its quarterly earnings data on Monday, November 7th. The biopharmaceutical company reported ($0.90) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.75) by $0.15. Dynavax Technologies Corp. had a negative return on equity of 78.57% and a negative net margin of 2,650.25%. The company had revenue of $0.20 million for the quarter, compared to the consensus estimate of $2.44 million. During the same quarter in the prior year, the company earned ($0.82) EPS. The company’s revenue for the quarter was down 83.3% on a year-over-year basis. Equities analysts expect that Dynavax Technologies Corp. will post ($3.21) earnings per share for the current fiscal year.

Hedge funds and other institutional investors have recently bought and sold shares of the company. State Street Corp raised its position in Dynavax Technologies Corp. by 49.1% in the first quarter. State Street Corp now owns 1,665,452 shares of the biopharmaceutical company’s stock worth $32,038,000 after buying an additional 548,310 shares during the last quarter. Senvest Management LLC raised its position in shares of Dynavax Technologies Corp. by 43.9% in the third quarter. Senvest Management LLC now owns 1,436,016 shares of the biopharmaceutical company’s stock worth $15,064,000 after buying an additional 438,285 shares in the last quarter. Morgan Stanley raised its position in shares of Dynavax Technologies Corp. by 108.2% in the third quarter. Morgan Stanley now owns 604,358 shares of the biopharmaceutical company’s stock worth $6,340,000 after buying an additional 314,073 shares in the last quarter. UBS Asset Management Americas Inc. raised its position in shares of Dynavax Technologies Corp. by 50.2% in the third quarter. UBS Asset Management Americas Inc. now owns 808,703 shares of the biopharmaceutical company’s stock worth $8,483,000 after buying an additional 270,280 shares in the last quarter. Finally, CQS Cayman LP raised its position in shares of Dynavax Technologies Corp. by 201.3% in the third quarter. CQS Cayman LP now owns 316,582 shares of the biopharmaceutical company’s stock worth $3,321,000 after buying an additional 211,500 shares in the last quarter. 85.18% of the stock is currently owned by institutional investors and hedge funds.

About Dynavax Technologies Corp.

Dynavax Technologies Corporation (Dynavax) is a clinical-stage biopharmaceutical company. The Company uses toll-like receptor (TLR) biology to discover and develop vaccines and therapeutics. Its development programs are focused on vaccines and cancer immunotherapy. The Company’s lead vaccine product candidate is HEPLISAV-B, an investigational adult hepatitis B vaccine, which combines its TLR9 agonist adjuvant and recombinant hepatitis B surface antigen (rHBsAg).

5 Day Chart for NASDAQ:DVAX

Receive News & Stock Ratings for Dynavax Technologies Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies Corp. and related stocks with our FREE daily email newsletter.